- In May 2023, Eli Lilly and Company announced the expansion of its osteoporosis product portfolio by enhancing global distribution of raloxifene under the Evista brand, aiming to improve accessibility in emerging markets. This move reflects the company’s strategy to strengthen its leadership in women’s health and address the growing demand for osteoporosis treatment options, especially in regions with rising aging populations and underdiagnosed bone health conditions
- In April 2023, Teva Pharmaceutical Industries Ltd. launched a generic version of raloxifene hydrochloride tablets in several European countries, offering a cost-effective alternative to branded formulations. This launch is part of Teva’s commitment to expanding its generics portfolio and enhancing treatment affordability for postmenopausal women at risk of osteoporosis and invasive breast cancer
- In March 2023, Amneal Pharmaceuticals, Inc. received FDA approval for its generic raloxifene hydrochloride 60 mg tablets, positioning the company to serve the U.S. market with a therapeutically equivalent, high-quality solution. The approval reinforces Amneal’s focus on increasing access to essential therapies and underscores the importance of generics in reducing healthcare costs
- In February 2023, Cipla Limited introduced raloxifene tablets in India under its women’s health division, targeting the increasing incidence of osteoporosis among postmenopausal women. The launch complements Cipla’s broader initiative to address chronic conditions affecting the aging population and reflects the company’s proactive approach to improving long-term patient outcomes
- In January 2023, Aurobindo Pharma Limited announced the successful commercialization of its raloxifene hydrochloride product across several Latin American markets. This strategic move aligns with the company’s international growth plans and addresses the rising demand for affordable osteoporosis therapies in regions with limited access to branded medications
